Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic Vaccines and Preventive Vaccines), Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020

免疫療法用治療薬の世界市場:単クローン抗体、インターフェロンα、インターロイキン、ワクチン、チェックポイント阻害薬

◆タイトル:Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic Vaccines and Preventive Vaccines), Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020
◆商品コード:MAM-PH-3926
◆調査・発行会社:MarketsandMarkets
◆発行日:2015年12月1日
◆ページ数:127
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD5,650 ⇒換算¥627,150見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥738,150見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥904,650見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、免疫療法用治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、治療薬種類別分析、地域別分析、市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

The immunotherapy drugs market is expected to grow at a CAGR of 12.8% to reach USD 73,529.2 Million by 2020. The growing focus on cancer therapies with fewer side effects is a key factor driving the growth of the global immunotherapy drugs market. Other factors driving the market include high prevalence rate of lifestyle diseases including cancer, fast track and orphan drug designations expediting the review of drugs. Factors such as high costs of treatment and lesser number of products getting approved are expected to restrict market growth. On the other hand significant growth prospects in the developing economies and high potential of immunotherapy to get approved as first line treatment are the major opportunities in the market.

The immunotherapy drugs market is broadly segmented on the basis of type of drug and geography. The major types of drugs considered include monoclonal antibodies, interferons alpha, interleukins, and vaccines. Among these drugs, monoclonal antibodies are expected to command the largest share while checkpoint Inhibitors is expected to grow at the fastest rate. Both categories of drugs are targeted therapies which act upon the targets that cannot be captured by small-molecule drugs and precisely identify and attack diseased cells, while doing little damage to normal cells.

On the basis of region, the immunotherapy drugs market is segmented into North America, Europe, Asia-Pacific and Rest of the World. (RoW). The North American geographic segment is expected to account for the largest share of immunotherapy drugs market, followed by Europe in 2015. Cancer is one of the highest funded topics of research in North America due to which this segment has gained special focus for research of cancer immunotherapy. Other driving factors include quicker drug approvals by Food and Drug Administration (FDA) and growth in population as well as aging of the population which are also responsible for rapid growth of the immunotherapy drugs market in North America.

Major players operating in the immunotherapy drugs market are Amgen Inc. (U.S.), GlaxoSmithKline Plc. (U.K.), Merck & Co., Inc. (U.S.), Novartis International Ag (Switzerland),and Roche Holding Ag (Switzerland).

【レポートの目次】

1 Introduction (Page No. – 13)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 16)
2.1 Market Size Estimation
2.2 Market Breakdown and Data Triangulation
2.2.1 Key Data From Secondary Sources
2.2.2 Key Data From Primary Sources
2.2.2.1 Key Industry Insights
2.2.3 Assumptions for the Study

3 Executive Summary (Page No. – 23)

4 Premium Insights (Page No. – 26)
4.1 Immunotherapy Drugs Market to Grow at A Rapid Rate
4.2 Global Immunotherapy Drugs Market Size
4.3 Geographical Snapshot of the Immunotherapy Drugs Market
4.4 Immunotherapy Drugs Market, By Type of Drug
4.5 Lifecycle Analysis, By Region

5 Market Overview (Page No. – 30)
5.1 Introduction
5.2 Market Segmentation
5.3 Market Dynamics
5.4 Drivers
5.4.1 Increasing Adoption of Targeted Therapy Over Traditional Therapy
5.4.2 Reduction in Overall Timeline and Cost for Drug Discovery
5.4.3 High Prevalence Rate of Lifestyle Diseases
5.4.4 Fast Track and Orphan Drug Designations
5.5 Restraints
5.5.1 High Cost of Immunotherapy Treatment
5.5.2 High Attrition Rate in the Product Development Cycle
5.6 Opportunities
5.6.1 Significant Growth Prospects in Developing Countries
5.6.2 Immunotherapy to Replace Chemotherapy as A First-Line Therapy
5.7 Challenges
5.7.1 Patent Expiries of Top-Selling Biologics

6 Cancer Immunotherapy Market- Industry Insights (Page No. – 36)
6.1 Cancer Epidemiology
6.1.1 Estimated Incidence, Mortality, and 5-Year Prevalence: Men (2012)
6.1.2 Estimated Incidence, Mortality, and 5-Year Prevalence: Women
6.1.3 Estimated Incidence, Mortality, and 5-Year Prevalence: Both Sexes (2012)
6.2 Pricing and Reimbursement
6.2.1 U.S.
6.2.2 U.K.
6.2.3 France
6.2.4 Germany
6.2.5 Other European Countries
6.2.6 Japan
6.3 Pipeline
6.3.1 Phase 1
6.3.2 Phase I/II
6.3.3 Phase II
6.3.4 Phase II/III
6.3.5 Phase III
6.3.6 Application Submitted
6.4 Promising Molecules
6.5 Treatment Protocols and Line of Therapies
6.5.1 First Line Therapy
6.5.2 Second Line Therapy
6.5.3 Other Treatments

7 Immunotherapy Drugs Market, By Type of Drugs (Page No. – 63)
7.1 Introduction
7.2 Monoclonal Antibodies
7.3 Interferons
7.4 Interleukins
7.5 Vaccines
7.6 Checkpoint Inhibitors

8 Global Immunotherapy Drugs Market, By Region (Page No. – 76)
8.1 Introduction
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.4 Asia-Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.5 Rest of the World (RoW)

9 Competitive Landscape (Page No. – 94)
9.1 Overview
9.2 Market Share Analysis
9.3 Competitive Situation and Trends
9.3.1 Approvals
9.3.2 Agreements, Partnerships, and Collaborations
9.3.3 Acqusitions

10 Company Profiles (Page No. – 100)
10.1 Introduction
10.2 F. Hoffmann-La Roche Ag
10.2.1 Business Overview
10.2.2 F. Hoffmann-La Roche Ag: Company Snapshot
10.2.3 Products Offered
10.2.4 Recent Developments
10.2.5 MnM View
10.3 Merck & Co., Inc.
10.3.1 Business Overview
10.3.2 Merck & Co., Inc.: Company Snapshot
10.3.3 Products Offered
10.3.4 Recent Developmen
10.3.5 MnM View
10.4 Novartis International Ag
10.4.1 Business Overview
10.4.2 Novartis International Ag: Company Snapshot
10.4.3 Products Offered
10.4.4 Recent Developments
10.4.5 MnM View
10.5 Glaxosmithkline Plc
10.5.1 Business Overview
10.5.2 Glaxosmithkline Plc: Company Snapshot
10.5.3 Product Offered
10.5.4 Recent Developments
10.5.5 MnM View
10.6 Amgen Inc.
10.6.1 Business Overview
10.6.2 Amgen Inc.: Company Snapshot
10.6.3 Products Offered
10.6.4 Recent Developments
10.6.5 MnM View
10.7 Bristol-Myers Squibb
10.7.1 Business Overview
10.7.2 Bristol-Myers Squibb: Company Snapshot
10.7.3 Products Offered
10.7.4 Recent Developments
10.8 ELI Lilly and Company
10.8.1 Business Overview
10.8.2 ELI Lilly and Company: Company Snapshot
10.8.3 Product Offered
10.8.4 Recent Developments
10.9 Celgene Corporation
10.9.1 Business Overview
10.9.2 Celgene Corporation: Company Snapshot
10.9.3 Products Offered
10.9.4 Recent Development
10.10 Seattle Genetics, Inc.
10.10.1 Business Overview
10.10.2 Seattle Genetics, Inc.: Company Snapshot
10.10.3 Product Offered
10.10.4 Recent Developments
10.11 Spectrum Pharmaceuticals, Inc.
10.11.1 Business Overview
10.11.2 Spectrum Phrmaceuticals, Inc.: Company Snapshot
10.11.3 Product Offered
10.11.4 Recent Developments

11 Appendix (Page No. – 121)
11.1 Insights of Industry Experts
11.2 Discussion Guide
11.3 Introducing RT: Real-Time Market Intelligence
11.4 Available Customizations
11.5 Related Reports

List of Tables (37 Tables)

Table 1 Global Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 2 Global Monoclonal Antibody Drugs Market Size, By Region, 2013-2020 (USD Million)
Table 3 North America: Monoclonal Antibody Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 4 Europe: Monoclonal Antibody Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 5 Asia-Pacific: Monoclonal Antibody Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 6 Global Interferon Drugs Market Size, By Region, 2013-2020 (USD Million)
Table 7 North America: Interferon Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 8 Europe: Interferon Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 9 Asia-Pacific: Interferon Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 10 Global Interleukin Drugs Market Size, 2013-2020 (USD Million)
Table 11 Global Vaccines Market Size, By Region, 2013-2020 (USD Million)
Table 12 Global Vaccines Market Size, By Type, 2013-2020 (USD Million)
Table 13 North America: Vaccines Market Size, By Country, 2013-2020 (USD Million)
Table 14 Europe: Vaccines Market Size, By Country, 2013-2020 (USD Million)
Table 15 Asia-Pacific: Vaccines Market Size, By Country, 2013-2020 (USD Million)
Table 16 Global Checkpoint Inhibitor Drugs Market Size, By Region, 2013-2020 (USD Million)
Table 17 North America: Checkpoint Inhibitor Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 18 Europe: Checkpoint Inhibitor Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 19 Asia-Pacific: Checkpoint Inhibitor Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 20 Global Immunotherapy Drugs Market Size, By Region, 2013–2020 (USD Million)
Table 21 North America: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 22 U.S.: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 23 Canada: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 24 Europe: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 25 Germany: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 26 U.K.: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 27 France: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 28 Italy: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 29 Spain: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 30 APAC: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 31 Japan: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 32 China: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 33 India: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 34 RoW: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 35 Approvals, 2013–2015
Table 36 Agreements, Partnerships, and Collaborations, 2013–2015
Table 37 Acqusitions, 2013-2015

List of Figures (29 Figures)

Figure 1 Research Design: Immunotherapy Drugs Market
Figure 2 Market Size Estimation
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Data Triangulation Methodology
Figure 5 Immunotherapy Drugs Market Snapshot (2015 vs 2020): Checkpoint Inhibitors Will Grow at the Highest Rate in the Next Five Years
Figure 6 Global Immunotherapy Drugs Market, By Type of Drug, 2015
Figure 7 Global Immunotherapy Drugs Market Share, 2015
Figure 8 Changing Demograhics and Focus on Targeted Therapies to Drive Market Growth
Figure 9 Monoclonal Antibodies to Account for the Largest Share of the Market in 2015
Figure 10 APAC to Grow at the Highest Rate During the Forecast Period
Figure 11 Checkpoint Inhibitors Expected to Be the Fastest Growing Segment
Figure 12 North America and APAC Markets Hold Lucrative Growth Opportunities
Figure 13 Market Segmentation
Figure 14 Global Immunotherapy Drugs Market: Drivers, Restraints, Opportunities & Challenges
Figure 15 Monoclonal Antibodies Segment is Expected to Dominate the Market in 2015
Figure 16 Interferon Drugs Market in APAC to Witness Highest Growth From 2015 to 2020
Figure 17 Therapeutic Vaccines to Witness Higher Growth in the Forecast Period
Figure 18 North America to Witness Highest Growth in the Checkpoint Inhibitors Market From 2015 to 2020
Figure 19 Geographic Snapshot (2015): Asia-Pacific Will Be the Fastest-Growing Region By 2020
Figure 20 North America, an Attractive Destination for Monoclonal Antibodies and Checkpoint Inhibitors
Figure 21 North America: Immunotherapy Drugs Market Snapshot
Figure 22 The Checkpoint Inhibitors Segment is the Fastest-Growing Market Segment in the U.S.
Figure 23 The Monoclonal Antibodies Segment to Dominate the Immunotherapy Drugs Market in Europe During the Forecast Period
Figure 24 APAC: Immunotherapy Drugs Market Snapshot
Figure 25 The Increasing Number of Key Market Players Focusing on Latin American Countries is Driving the Immunotherapy Drugs Market in the RoW Region
Figure 26 Companies Adopted New Product Launches and Approvals as Their Key Growth Strategy Over the Last Three Years
Figure 27 Global Immunotherapy Drugs Market Share Analysis, By Key Player, 2014
Figure 28 Battle for Market Share: Approvals Was the Key Growth Strategy Adopted By Market Players From 2013 to 2015
Figure 29 Geographic Revenue Mix of the Top Four Market Players

【レポートのキーワード】

免疫療法用治療薬、単クローン抗体、インターフェロンα、インターロイキン、免疫ワクチン、治療ワクチン、予防ワクチン、免疫チェックポイント阻害薬、医薬品

★調査レポート[免疫療法用治療薬の世界市場:単クローン抗体、インターフェロンα、インターロイキン、ワクチン、チェックポイント阻害薬] ( Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic Vaccines and Preventive Vaccines), Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020 / MAM-PH-3926) 販売に関する免責事項
[免疫療法用治療薬の世界市場:単クローン抗体、インターフェロンα、インターロイキン、ワクチン、チェックポイント阻害薬] ( Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic Vaccines and Preventive Vaccines), Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020 / MAM-PH-3926) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆